Astellas Pharma (4503) Aktienübersicht
Astellas Pharma Inc. produziert, vermarktet, importiert und exportiert pharmazeutische Produkte in Japan und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 5/6 |
Belohnungen
Risikoanalyse
4503 Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Astellas Pharma Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | JP¥2,151.00 |
| 52-Wochen-Hoch | JP¥2,717.00 |
| 52-Wochen-Tief | JP¥1,422.50 |
| Beta | 0.084 |
| 1 Monat Veränderung | 0.26% |
| 3 Monate Veränderung | -13.98% |
| 1 Jahr Veränderung | 51.16% |
| 3 Jahre Veränderung | 3.41% |
| 5 Jahre Veränderung | 12.50% |
| Veränderung seit IPO | 265.82% |
Aktuelle Nachrichten und Updates
Analyseartikel • Jun 23
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Even though Astellas Pharma Inc.'s ( TSE:4503 ) recent earnings release was robust, the market didn't seem to notice...
Narrative-Update • Jun 23
4503: KRAS Oncology And AI Overhaul Will Likely Strain Future Returns
The latest analyst update on Astellas Pharma edges the fair value estimate from ¥1,669.63 to ¥1,701.65, with the modest change tied to revised assumptions on revenue trends, profit margins, and projected future P/E levels. What’s in the News for Astellas Pharma Astellas Pharma is internalizing clinical operations and adopting artificial intelligence tools in drug development, with a focus on improving clinical trial efficiency and decision making.
Narrative-Update • Jun 07
4503: CSP2026 Oncology Pipeline And Dividends Will Drive Future Upside Potential
Analysts are holding their ¥2,950 price target for Astellas Pharma, with updated assumptions indicating softer revenue growth, higher profit margins, and a lower future P/E, which together help support the unchanged valuation. What's in the News Astellas announced its five year Corporate Strategic Plan "CSP2026," targeting 10 or more Phase 3 or pivotal studies by fiscal 2030 and aiming to double revenue from its Strategic Brands, with an objective of record high revenue in the mid 2030s and ongoing annual dividend increases (source: Astellas CSP2026 announcement).Recent updates
Analyseartikel • Jun 23
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Even though Astellas Pharma Inc.'s ( TSE:4503 ) recent earnings release was robust, the market didn't seem to notice...Narrative-Update • Jun 23
4503: KRAS Oncology And AI Overhaul Will Likely Strain Future Returns
The latest analyst update on Astellas Pharma edges the fair value estimate from ¥1,669.63 to ¥1,701.65, with the modest change tied to revised assumptions on revenue trends, profit margins, and projected future P/E levels. What’s in the News for Astellas Pharma Astellas Pharma is internalizing clinical operations and adopting artificial intelligence tools in drug development, with a focus on improving clinical trial efficiency and decision making.Narrative-Update • Jun 07
4503: CSP2026 Oncology Pipeline And Dividends Will Drive Future Upside Potential
Analysts are holding their ¥2,950 price target for Astellas Pharma, with updated assumptions indicating softer revenue growth, higher profit margins, and a lower future P/E, which together help support the unchanged valuation. What's in the News Astellas announced its five year Corporate Strategic Plan "CSP2026," targeting 10 or more Phase 3 or pivotal studies by fiscal 2030 and aiming to double revenue from its Strategic Brands, with an objective of record high revenue in the mid 2030s and ongoing annual dividend increases (source: Astellas CSP2026 announcement).Narrative-Update • May 24
4503: Rising Bladder Cancer Setback Risks Will Likely Pressure Future Returns
Astellas Pharma's analyst price target has shifted from a fair value of ¥1,500 to about ¥1,670 as analysts factor in a higher assumed discount rate, softer revenue and profit expectations, and a higher future P/E multiple in their updated models. What's in the News Astellas plans to present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, including a 3.5-year follow up from the Phase 3 EV-302 study of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer, along with multiple prostate cancer and vasomotor symptom studies.
Narrative-Update • May 02
4503: Bladder Cancer Progress And Updated Guidance Will Shape Fairly Balanced Outlook
Analysts have slightly reduced their fair value estimate for Astellas Pharma from about ¥2,407 to about ¥2,396, citing updated assumptions that include a softer revenue outlook, a higher projected profit margin, and a lower future P/E multiple. What's in the News Astellas and Pfizer reported positive Phase 3 EV-304 data for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) in muscle invasive bladder cancer, with the regimen linked to a 47% lower risk of tumor recurrence, progression or death and a 35% lower risk of death compared with standard chemotherapy, along with a higher pathological complete response rate and no new safety signals (Key Developments).Analyseartikel • Apr 30
Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Astellas Pharma Inc. ( TSE:4503 ) shareholders are probably feeling a little disappointed, since its shares fell 7.8...Narrative-Update • Apr 17
4503: Bladder Cancer Data And Guidance Will Temper Risks From Weaker Legacy Portfolio
Analysts have nudged their fair value estimate for Astellas Pharma higher from ¥2,100 to about ¥2,407, citing updated assumptions for revenue trends, profit margins, and a slightly lower future P/E multiple. What's in the News Astellas and HOVON reported that the Phase 3 HOVON 156 / AMLSG 28-18 / PASHA study of XOSPATA (gilteritinib) versus midostaurin-based treatment in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, with Astellas indicating it expects a minor impact on financial results for the fiscal year ending March 31, 2026 (Key Developments).Narrative-Update • Apr 02
4503: Future Oncology Pipeline And Partnerships Will Support Upside Potential
The analyst price target for Astellas Pharma has been revised from ¥2,700 to ¥2,950, with analysts citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple as key drivers behind the change. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, and Astellas plans a full data review and expects only a minor impact on fiscal 2026 results.Narrative-Update • Mar 19
4503: Trial Setbacks And Weaker Margins Will Likely Pressure Future Returns
Analysts have kept Astellas Pharma's fair value estimate steady at ¥1,500, while slightly adjusting assumptions for discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power, without changing the overall price target level. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint.Narrative-Update • Mar 05
4503: Bladder Cancer Pipeline Dependence Will Increase Execution Risk Versus Weakening Revenue Outlook
Astellas Pharma's analyst price target has been adjusted from ¥1,938 to ¥2,100, with analysts pointing to updated assumptions around a slightly higher discount rate, softer revenue growth, a modestly stronger profit margin and a higher future P/E multiple to support the new view. What's in the News Pfizer and Astellas reported positive Phase 3 EV-304 results for PADCEV in combination with Keytruda in muscle invasive bladder cancer.Narrative-Update • Feb 19
4503: Revised Earnings Outlook And Clinical Progress Will Support Balanced Future Upside
Analysts have adjusted their view on Astellas Pharma, raising the price target from ¥2,400 to ¥2,700, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Astellas revised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, with similar revisions on a full basis.Analyseartikel • Feb 08
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Astellas Pharma Inc. ( TSE:4503 ) defied analyst predictions to release its quarterly results, which were ahead of...Narrative-Update • Feb 05
4503: Elevated Earnings Outlook Will Likely Mask Higher Long Term Margin Risks
Analysts have increased their fair value estimate for Astellas Pharma from ¥1,300 to ¥1,500, citing updated assumptions that include a revised revenue growth profile, higher projected profit margins, and a lower anticipated future P/E multiple. What's in the News Astellas raised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, supported by XTANDI and mirabegron products and foreign exchange effects (Key Developments).Analyseartikel • Feb 05
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...Narrative-Update • Jan 22
4503: Rising Bladder Cancer Reliance Will Increase Execution Risk Versus Softer Revenue Outlook
Analysts have nudged their fair value estimate for Astellas Pharma up from ¥1,884.62 to ¥1,938.46, citing updated assumptions around slightly softer revenue growth, a modestly higher profit margin, and a small adjustment to the future P/E multiple. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, which keeps attention on deal activity in ophthalmology and broader specialty pharma (Investor's Business Daily).Analyseartikel • Jan 19
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend on the 3rd of June, with...Narrative-Update • Jan 07
4503: Rising Bladder Cancer Pipeline Reliance Will Increase Execution And Partnering Risks
Analysts have modestly raised their fair value estimate for Astellas Pharma from ¥1,792.14 to ¥1,884.62, citing updated assumptions around slightly softer revenue contraction, a higher profit margin outlook, and a small adjustment to the future P/E multiple. What's in the News The U.S. FDA approved PADCEV in combination with Keytruda as perioperative treatment for adult patients with muscle invasive bladder cancer who are ineligible for cisplatin chemotherapy.Analyseartikel • Jan 05
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) will pay a dividend of ¥39.00 on the 3rd of June. This makes the dividend yield 3.7...Analyseartikel • Dec 17
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...Narrative-Update • Dec 14
4503: Early Veeva CRM Adoption Will Support Margin Expansion And Upside Potential
Analysts have nudged their price target on Astellas Pharma higher from ¥2,200 to ¥2,400, citing the company’s role among leading pharma adopters of Veeva’s upgraded CRM platform and a modestly improved long term profit margin outlook, despite slightly softer revenue growth assumptions. Analyst Commentary Bullish analysts point to Astellas Pharma’s early adoption of Veeva’s Vault CRM as a key validation of its digital commercial strategy, aligning the company with a growing roster of large global biopharma peers migrating to the upgraded platform.Analyseartikel • Dec 03
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd of June...Narrative-Update • Nov 29
4503: Major Partner Platform Commitments Will Shape Competitive Positioning And Execution Risks
Analysts have slightly raised their price target for Astellas Pharma to ¥1,792.14 from ¥1,774.29. They cite continued incremental commitments from major industry partners as a supportive factor for the company's outlook.Narrative-Update • Nov 15
4503: Digital Transformation Commitments Will Drive Operational Efficiency And Execution Risk Ahead
Astellas Pharma's fair value target has been raised slightly from ¥1,753 to ¥1,774. This reflects analysts' expectations of improved revenue and margin trends in light of a renewed commitment to digital transformation within the sector.Analyseartikel • Nov 07
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
When companies post strong earnings, the stock generally performs well, just like Astellas Pharma Inc.'s ( TSE:4503...Analyseartikel • Nov 03
Astellas Pharma Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Astellas Pharma Inc. ( TSE:4503 ) just kicked off its latest half-yearly results with some very...Narrative-Update • Nov 01
4503: Digital CRM Adoption And Margin Pressures Will Shape Medium-Term Performance
Analysts have revised their price target for Astellas Pharma to ¥1,752.86, citing a more cautious outlook on revenue growth and margin pressures. This update reflects recent industry research and changes in competitive dynamics.Narrative-Update • Oct 17
Oncology And Rare Diseases Trends Will Unlock Global Potential
Astellas Pharma's analyst price target has increased slightly from ¥1,749.29 to ¥1,752.86. Analysts cite ongoing partnerships with industry leaders and an improved outlook on core platform adoption as contributing factors.Narrative-Update • Oct 03
Oncology And Rare Diseases Trends Will Unlock Global Potential
Analysts have raised their price target for Astellas Pharma from ¥1,725 to ¥1,749, citing steady fundamentals and ongoing industry commitments. These points were highlighted in recent sector developments.Analyseartikel • Sep 19
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Narrative-Update • Sep 18
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a further decline in consensus revenue growth forecasts, Astellas Pharma’s analyst price target inched up from ¥1708 to ¥1725, reflecting only a marginal increase in perceived fair value. What's in the News Positive Phase 3 results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin; significant improvement in event-free and overall survival compared to surgery alone, with consistent safety profiles.Narrative-Update • Aug 27
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a notable improvement in consensus revenue growth forecasts, Astellas Pharma’s fair value was revised only slightly lower, with the analyst price target decreasing marginally from ¥1711 to ¥1692. What's in the News Positive Phase 3 EV-303 trial results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer show clinically meaningful improvements in event-free and overall survival versus surgery alone.Analyseartikel • Aug 12
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Analyseartikel • Aug 01
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Astellas Pharma Inc. ( TSE:4503 ) just released its latest quarterly results and things are looking bullish. The...Analyseartikel • Jul 24
Astellas Pharma (TSE:4503) Is Increasing Its Dividend To ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Aktionärsrenditen
| 4503 | JP Pharmaceuticals | JP Markt | |
|---|---|---|---|
| 7D | 0.2% | 1.3% | -3.2% |
| 1Y | 51.2% | 17.1% | 37.5% |
Rendite im Vergleich zur Industrie: 4503 übertraf die Branche JP Pharmaceuticals , die im vergangenen Jahr eine Rendite von 17.1 erzielte.
Rendite vs. Markt: 4503 übertraf den Markt JP, der im vergangenen Jahr eine Rendite von 37.5 erzielte.
Preisvolatilität
| 4503 volatility | |
|---|---|
| 4503 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 2.1% |
Stabiler Aktienkurs: 4503 hatte in den letzten 3 Monaten im Vergleich zum JP -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 4503Die wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1923 | 14,099 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. produziert, vermarktet, importiert und exportiert Pharmazeutika in Japan und international. Das Unternehmen bietet XTANDI, ein Medikament zur Behandlung von Prostatakrebs, XOSPATA, ein Medikament zur Behandlung von Patienten mit rezidivierender oder refraktärer akuter myeloischer Leukämie mit einer FLT3-Mutation, und PADCEV, ein Medikament zur Behandlung von Patienten mit metastasierendem Urothelkrebs. Darüber hinaus bietet das Unternehmen Evrenzo zur Behandlung von Anämie im Zusammenhang mit chronischen Nierenerkrankungen, Betanis/Myrabetriq/BETMIGA zur Behandlung der überaktiven Blase sowie die Immunsuppressiva Prograf und Advagraf/Graceptor/ASTAGRAF XL an.
Astellas Pharma Inc.'s Grundlagenzusammenfassung
| 4503 grundlegende Statistiken | |
|---|---|
| Marktanteil | JP¥3.85t |
| Gewinn(TTM) | JP¥291.54b |
| Umsatz(TTM) | JP¥2.14t |
13.2x
Kurs-Gewinn-Verhältnis 1.8x
Kurs-Umsatz-VerhältnisIst 4503 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 4503 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | JP¥2.14t |
| Kosten der Einnahmen | JP¥408.43b |
| Bruttogewinn | JP¥1.73t |
| Sonstige Ausgaben | JP¥1.44t |
| Gewinn | JP¥291.54b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 05, 2026
| Gewinn per Aktie (EPS) | 162.73 |
| Bruttomarge | 80.91% |
| Nettogewinnspanne | 13.63% |
| Schulden/Eigenkapital-Verhältnis | 30.9% |
Wie hat sich 4503 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
3.7%
Aktuelle Dividendenrendite48%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/21 06:35 |
| Aktienkurs zum Tagesende | 2026/07/17 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Astellas Pharma Inc. wird von 24 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |